Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Operating Expenses (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Operating Expenses for 8 consecutive years, with $24.9 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 4.97% to $24.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $121.5 million through Dec 2025, up 30.08% year-over-year, with the annual reading at $121.5 million for FY2025, 30.08% up from the prior year.
  • Operating Expenses for Q4 2025 was $24.9 million at Whitehawk Therapeutics, up from $19.5 million in the prior quarter.
  • The five-year high for Operating Expenses was $87.3 million in Q3 2021, with the low at $3.9 million in Q2 2021.
  • Average Operating Expenses over 5 years is $25.1 million, with a median of $22.1 million recorded in 2022.
  • The sharpest move saw Operating Expenses soared 2916.97% in 2021, then plummeted 77.92% in 2022.
  • Over 5 years, Operating Expenses stood at $16.9 million in 2021, then grew by 22.15% to $20.7 million in 2022, then increased by 16.14% to $24.0 million in 2023, then grew by 8.94% to $26.2 million in 2024, then dropped by 4.97% to $24.9 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $24.9 million, $19.5 million, and $54.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.